KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments: 2020-2023

Historic Change in Acquisitions & Divestments for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2023 value amounting to $480,000.

  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments fell 99.22% to $480,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $231.1 million, marking a year-over-year decrease of 22.92%. This contributed to the annual value of $480,000 for FY2023, which is 99.79% down from last year.
  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments amounted to $480,000 in FY2023, which was down 99.79% from $230.6 million recorded in FY2022.
  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $230.6 million during FY2022, with a 5-year trough of $480,000 in FY2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $100.1 million, with a median of $69.2 million in 2021.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Change in Acquisitions & Divestments surged by 11,528.74% in 2021 and then crashed by 99.79% in 2023.
  • Over the past 4 years, Recursion Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $595,000 in 2020, then surged by 11,528.74% to $69.2 million in 2021, then soared by 233.29% to $230.6 million in 2022, then slumped by 99.79% to $480,000 in 2023.